查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1841995

全球先進癌症診斷市場：市場規模、佔有率和趨勢分析（按檢測、最終用途和地區分類），細分市場預測（2025-2033 年）

Advanced Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

先進癌症診斷市場摘要

全球先進癌症診斷市場預計在 2024 年達到 583 億美元，預計到 2033 年將達到 1,270.7 億美元，2025 年至 2033 年的複合年成長率為 9.05%。

市場受多種強大因素驅動：全球癌症發生率不斷上升，持續推動對早期準確檢測的需求；及時診斷提高患者生存率，推動基因組學、分子生物學和圖像學工具的普及應用。

液態切片、人工智慧病理檢測和生物標記伴隨診斷等突破性技術正在加速精準腫瘤學的發展，從而實現更個人化和有效的治療。成本效益也是一個重要的促進因素，案例研究表明，診斷技術可以透過減少後期治療和副作用，顯著降低醫療成本。同時，不斷擴大的報銷框架和諸如ECII等大型舉措正在改善患者的可及性和接受度。

先進癌症診斷的市場動態受到快速的技術進步、不斷演變的政策框架以及醫療保健重點轉變的影響。過去，癌症的診斷和治療主要依據腫瘤的位置和分期，但先進診斷技術的出現改變了這個模式。這些新工具能夠深入了解癌症的分子、遺傳和生物學基礎，使精準醫療成為現實。透過實現更早、更準確的診斷，先進診斷技術降低了漏診和誤診的風險，從而為更個人化的治療方案打開了大門。這種更高的準確性最大限度地減少了患者接受無效治療及其相關副作用的風險，同時也能即時監測治療效果。

潛在的益處不僅限於改善病患預後，還能提升醫療體系的效率。整合先進診斷技術的醫療系統可以透過減少無效治療的需求和最大限度地減少因副作用導致的住院治療，從而顯著降低成本。在愛爾蘭的一項案例研究中，對大腸直腸癌患者進行特定基因突變檢測，幫助他們避免了嚴重的副作用，尤其是那些需要住院治療的副作用，最終為每位患者節省了超過5500萬美元。同樣，早期發現也能帶來顯著的成本效益。在乳癌領域，早期診斷已被證明可以降低近50%的醫療成本，與晚期疾病相比，這意味著每個患者群體可節省數億美元。

科技的應用也能為醫療系統本身節省資源。美國的一項案例研究表明，某學術醫療中心採用數位病理學技術，五年內節省了130萬美元，同時提高了診斷準確率，並將診斷審核時間縮短了30%以上。因此，人工智慧的整合正成為重塑工作流程效率和降低錯誤率的臨床和經濟催化劑。

同時，推廣應用仍面臨諸多障礙。先進的診斷技術目前仍局限於研究實驗室和專科醫院，限制了整個醫療保健系統公平取得這些技術的機會。監管和報銷方面的挑戰尤其嚴峻。傳統的監管框架並不適用於人工智慧診斷等適應性強的技術，這些技術即使在核准後仍會不斷發展。歐盟於2023年啟動的TEF-Health舉措獲得了近6,600萬美元的資金支持，堪稱監管創新的案例研究，它提供了一個在監督下測試新方法的沙盒環境。然而，體外診斷醫療設備法規（IVDR）的延遲實施凸顯了可能出現瓶頸的風險。分析師估計，多達27,400名癌症患者可能面臨臨床試驗參與延遲，這將導致數億美元的間接經濟損失和治療費用。

其他資金籌措模式也揭示了潛在效益的規模。澳洲於2016年推出的丙型肝炎報銷計劃，投入了7.92億美元，堪稱一項開創性的案例研究。該計劃預計到2030年將帶來41億美元的生產力提升和38億美元的淨經濟效益。將此類模式應用於腫瘤診斷領域，尤其是在液態切片和基因檢測等領域，可實現永續的普及和應用。

基礎建設也是一大挑戰。在許多歐洲醫療系統中，切片檢查樣本在最終分析前需要經過多個機構，這會延誤治療。在診斷時進行全基因組定序可以簡化此流程，但這需要大量投資。數據共用的障礙依然顯著。歐洲癌症影像計畫（ECII）於2023年啟動，已建立了一個價值超過5500萬美元的覆蓋整個歐洲大陸的癌症影像交換平台，為協作基礎設施建設提供了案例研究。這些措施旨在打破資訊孤島，擴展資料集，並加速診斷創新。

在技​​術方面，英國一項研究表明，液態切片比掃描提前3-5個月檢測出復發，每檢測100名腦腫瘤患者可節省7200萬美元。全身PET影像也取得了類似的進展，其靈敏度提高了40倍，同時縮短了掃描時間並降低了輻射劑量；多參數MRI則使超過25%的疑似前列腺癌患者免於接受侵入性切片檢查，相當於每年為整個醫療系統節省數億美元。

人工智慧正不斷整合這些進展。乳癌案例研究表明，人工智慧能夠檢測高HER2表達並改善患者分層，從而確保更精準的治療匹配，並帶來每年數千萬美元的系統級效率提升。與人工審核相比，計算病理學可將分析速度提高高達50%，同時維持或提高準確性。

來自愛爾蘭、美國、澳洲和英國的案例研究表明，先進的癌症診斷技術正在展現其臨床和經濟效益，並從願景走向實踐。然而，在監管、資金、基礎設施和公平性方面仍然存在差距。這些動態預示著未來將充滿機會與挑戰。如果政策制定者和產業領袖能夠攜手合作，調整法律規範，試點創新融資模式，投資數位化和診斷基礎設施，並確保公平應用，那麼先進的診斷技術不僅將改變癌症治療，還將在未來十年重塑醫療保健經濟格局。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章 市場因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場趨勢與展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • PESTEL分析
    • 波特五力分析
  • 新冠疫情影響分析

第4章 透過測試進行業務分析

  • 先進癌症診斷市場：按檢測方法分類的波動分析（2024 年和 2033 年）
  • 腫瘤標記檢測
    • 腫瘤標記檢測市場（2021-2033）
  • 細針穿刺細胞學檢查（FNAC）和切片檢查
    • 細針穿刺細胞學（FNAC）/切片檢查市場（2021-2033）
  • 影像學診斷
    • 診斷影像市場（2021-2033）
  • 骨髓穿刺和切片檢查
    • 骨髓穿刺和切片檢查市場（2021-2033）
  • 免疫組織化學（IHC）/分子檢測
    • 免疫組織化學（IHC）/分子檢測市場（2021-2033）
  • 基因檢測
    • 基因檢測市場（2021-2033）
  • 液態生物檢體
    • 液態生物檢體市場（2021-2033）

第5章 依最終用途進行業務分析

  • 先進癌症診斷市場：按最終用途分類的趨勢分析（2024 年和 2033 年）
  • 醫院和癌症中心
    • 醫院和癌症中心市場（2021-2033 年）
  • 診斷實驗室
    • 診斷實驗室市場（2021-2033）
  • 研究和學術機構
    • 研究與學術機構市場（2021-2033）
  • 製藥和生物技術公司
    • 醫藥和生物技術市場（2021-2033）
  • 其他
    • 其他市場（2021-2033 年）

第6章：區域商業分析

  • 區域市場概況
  • 北美洲
    • 北美高級癌症診斷市場（2021-2033）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲先進癌症診斷市場（2021-2033）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區先進癌症診斷市場（2021-2033）
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 拉丁美洲高級癌症診斷市場（2021-2033 年）
    • 主要國家的趨勢
    • 法律規範
    • 競爭場景
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲先進癌症診斷市場（2021-2033 年）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭情勢

  • 公司分類
  • 策略規劃
    • 企業收購
    • 商業合作
    • 新平台推出
    • 其他
  • 公司簡介/上市公司
    • Fujifilm Holdings Corporation
    • GE Healthcare
    • Siemens Healthineers
    • Philips Healthcare
    • Thermo Fisher Scientific
    • Illumina, Inc.
    • Agilent Technologies
    • Bio-Rad Laboratories
    • Canon Medical Systems
    • Bruker Corporation
    • BD
    • Bio-Rad Laboratories
    • Myriad Genetics
    • Roche Diagnostics
    • F. Hoffmann-La Roche Ltd.

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章：先進癌症診斷市場：影響因素、趨勢與範圍

  • 市場關聯性展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場趨勢與展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • PESTEL分析
    • 波特五力分析
  • 新冠疫情影響分析

第4章 透過測試進行業務分析

  • 先進癌症診斷市場：按檢測方法分類的波動分析（2024 年和 2033 年）
  • 腫瘤標記檢測
    • 腫瘤標記檢測市場（2021-2033）
  • 細針穿刺細胞學檢查（FNAC）和切片檢查
    • 細針穿刺細胞學（FNAC）/切片檢查市場（2021-2033）
  • 影像學診斷
    • 診斷影像市場（2021-2033）
  • 骨髓穿刺和切片檢查
    • 骨髓穿刺和切片檢查市場（2021-2033）
  • 免疫組織化學（IHC）/分子檢測
    • 免疫組織化學（IHC）/分子檢測市場（2021-2033）
  • 基因檢測
    • 基因檢測市場（2021-2033）
  • 液態生物檢體
    • 液態生物檢體市場（2021-2033）

第5章 依最終用途進行業務分析

  • 先進癌症診斷市場：按最終用途分類的趨勢分析（2024 年和 2033 年）
  • 醫院和癌症中心
    • 醫院和癌症中心市場（2021-2033 年）
  • 診斷實驗室
    • 診斷實驗室市場（2021-2033）
  • 研究和學術機構
    • 研究與學術機構市場（2021-2033）
  • 製藥和生物技術公司
    • 醫藥和生物技術市場（2021-2033）
  • 其他
    • 其他市場（2021-2033 年）

第6章：區域商業分析

  • 區域市場概況
  • 北美洲
    • 北美高級癌症診斷市場（2021-2033）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲先進癌症診斷市場（2021-2033）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區先進癌症診斷市場（2021-2033）
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 拉丁美洲高級癌症診斷市場（2021-2033 年）
    • 主要國家的趨勢
    • 法律規範
    • 競爭場景
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲先進癌症診斷市場（2021-2033 年）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭情勢

  • 公司分類
  • 策略規劃
    • 企業收購
    • 商業合作
    • 新平台推出
    • 其他
  • 公司簡介/上市公司
    • Fujifilm Holdings Corporation
    • GE Healthcare
    • Siemens Healthineers
    • Philips Healthcare
    • Thermo Fisher Scientific
    • Illumina, Inc.
    • Agilent Technologies
    • Bio-Rad Laboratories
    • Canon Medical Systems
    • Bruker Corporation
    • BD
    • Bio-Rad Laboratories
    • Myriad Genetics
    • Roche Diagnostics
    • F. Hoffmann-La Roche Ltd.
Product Code: GVR-4-68040-751-1

Advanced Cancer Diagnostics Market Summary

The global advanced cancer diagnostics market size was estimated at USD 58.30 billion in 2024 and is expected to reach USD 127.07 billion by 2033, expanding at a CAGR of 9.05% from 2025 to 2033. The market is driven by several strong factors. Rising global cancer incidence continues to expand demand for early and precise detection, while patient survival benefits from timely diagnosis are pushing adoption of genomic, molecular, and imaging-based tools.

Breakthroughs such as liquid biopsy, AI-enabled pathology, and biomarker-driven companion diagnostics are accelerating precision oncology, enabling more personalized and effective treatment. Cost-efficiency also acts as a driver, with case studies showing significant healthcare savings when diagnostics reduce late-stage treatments and adverse drug reactions. Alongside this, expanding reimbursement frameworks and large-scale initiatives like ECII are improving access and adoption.

The market dynamics for advanced cancer diagnostics are being shaped by rapid technological progress, evolving policy frameworks, and shifting healthcare priorities. Historically, cancer diagnosis and treatment were guided primarily by tumor location and stage, but the advent of advanced diagnostics has changed this paradigm. These new tools provide granular insights into the molecular, genetic, and biological underpinnings of cancer, making precision medicine a tangible reality. By enabling earlier and more accurate diagnosis, advanced diagnostics reduce the chances of missed or incorrect diagnoses and open the door to more personalized treatment selection. This precision minimizes patient exposure to ineffective therapies and their associated side effects, while also supporting real-time monitoring of treatment effectiveness.

The potential benefits extend beyond patient outcomes to health system efficiency. Health systems that integrate advanced diagnostics could see significant cost savings by reducing the need for ineffective treatments and minimizing hospitalizations from adverse drug reactions. One case study from Ireland illustrates this impact: testing colorectal cancer patients for specific genetic variations generated savings of more than USD 55 million per patient, primarily by avoiding severe side effects that would have required hospital care. Similarly, early detection yields strong cost advantages. In breast cancer, early-stage diagnosis has been shown to reduce medical costs by nearly 50%, equivalent to hundreds of millions of USD per patient cohort when compared with late-stage disease.

Technology adoption can also save resources within the health system itself. A U.S. case study demonstrated that the use of digital pathology at an academic medical center delivered savings of USD 1.3 million over five years, while simultaneously improving accuracy and cutting diagnostic review times by more than 30%. Artificial intelligence integration thus emerges as both a clinical and economic catalyst, reshaping workflow efficiency and lowering error rates.

At the same time, barriers to adoption remain significant. Advanced diagnostics are still largely restricted to research facilities or specialist hospitals, meaning equitable access across wider health systems is limited. Regulatory and reimbursement challenges are particularly acute. Traditional frameworks are not well-suited to adaptive technologies like AI-based diagnostics, which continue to evolve after approval. The EU's TEF-Health initiative, launched in 2023 with funding of nearly USD 66 million, serves as a case study of regulatory innovation, providing a sandbox for real-world testing of new approaches under supervision. Yet, delays tied to the rollout of the In Vitro Diagnostic Medical Devices Regulation (IVDR) highlight the risks of bottlenecks. Analysts estimate that up to 27,400 cancer patients may face delays in clinical trial access, translating into indirect economic and treatment costs of several hundred million USD.

Alternative funding models also reveal the scale of potential benefits. Australia's reimbursement scheme for hepatitis C, introduced in 2016 with funding of USD 792 million, stands as a landmark case study. The program secured projected productivity gains worth USD 4.1 billion and a net economic benefit of USD 3.8 billion by 2030. Applying such models to oncology diagnostics could unlock sustainable access and uptake, particularly in areas like liquid biopsy and genetic testing.

Infrastructure remains another challenge. In many European health systems, biopsy samples still travel across multiple facilities before reaching final analysis, delaying care. Whole-genome sequencing at diagnosis could streamline this process, but requires large-scale investments. Data-sharing barriers also remain critical. The European Cancer Imaging Initiative (ECII), launched in 2023, provides a case study of collaborative infrastructure, establishing a continent-wide platform for cancer image exchange worth more than USD 55 million. Such efforts aim to break down silos, broaden datasets, and accelerate diagnostic innovation.

On the technology front, Liquid biopsy, as demonstrated in a study from England, detected relapse three to five months earlier than scans and saved USD 72 million for every 100 brain tumor patients tested. Similar advances are being seen with total-body PET imaging, which improves sensitivity 40-fold while lowering scan time and radiation dose, and with multiparametric MRI, which has already spared more than 25% of suspected prostate cancer patients from invasive biopsies, amounting to system-level savings in the hundreds of millions of USD annually.

Artificial intelligence continues to unify these advances. A case study in breast cancer demonstrated AI's ability to detect high HER2 expression and improve patient stratification, ensuring better treatment matching and delivering system-level efficiencies worth tens of millions of USD per year. Computational pathology further accelerates analysis by up to 50% compared to manual reviews, while maintaining or improving accuracy.

The advanced cancer diagnostics are moving from promise to practice, with case studies across Ireland, the U.S., Australia, and England proving their clinical and economic impact. Yet, gaps in regulation, funding, infrastructure, and equity remain. These dynamics suggest a future defined by both opportunities and challenges. If policymakers and industry leaders act in tandem adapting regulatory frameworks, piloting innovative funding models, investing in digital and diagnostic infrastructure, and ensuring equitable implementation advanced diagnostics will not only transform cancer care but also reshape healthcare economics across the next decade.

Global Advanced Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For the purpose of this report, Grand View Research has segmented the global advanced cancer diagnostics market report on the basis of test, end use, and region:

  • Test Outlook (Revenue, USD Billion, 2021 - 2033)
  • Tumor Marker Tests
  • Fine Needle Aspiration Cytology (FNAC) & Biopsy
  • Imaging-Based Diagnostics
  • Bone Marrow Aspiration & Biopsy
  • Immunohistochemistry (IHC) & Molecular Testing
  • Genetic Testing for Cancer
  • Liquid Biopsy
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals & Cancer Specialty Centers
  • Diagnostic Laboratories (Independent & Reference Labs)
  • Research & Academic Institutes
  • Pharmaceutical & Biotechnology Companies
  • Others
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Market Definitions
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Cancer Type and End Use Snapshot
  • 2.3. Technique and End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTLE Analysis
    • 3.4.2. Porter's Five Forces Analysis
  • 3.5. COVID-19 Impact Analysis

Chapter 4. Test Business Analysis

  • 4.1. Advanced Cancer Diagnostics Market: Test Movement Analysis, 2024 & 2033
  • 4.2. Tumor Marker Tests
    • 4.2.1. Tumor Marker Tests Market, 2021 - 2033 (USD Billion)
  • 4.3. Fine Needle Aspiration Cytology (FNAC) & Biopsy
    • 4.3.1. Fine Needle Aspiration Cytology (FNAC) & Biopsy market, 2021 - 2033 (USD Billion)
  • 4.4. Imaging-Based Diagnostics
    • 4.4.1. Imaging-Based Diagnostics market, 2021 - 2033 (USD Billion)
  • 4.5. Bone Marrow Aspiration & Biopsy
    • 4.5.1. Bone Marrow Aspiration & Biopsy market, 2021 - 2033 (USD Billion)
  • 4.6. Immunohistochemistry (IHC) & Molecular Testing
    • 4.6.1. Immunohistochemistry (IHC) & Molecular Testing market, 2021 - 2033 (USD Billion)
  • 4.7. Genetic Testing
    • 4.7.1. Genetic Testing Market, 2021 - 2033 (USD Billion)
  • 4.8. Liquid Biopsy
    • 4.8.1. Liquid Biopsy Market, 2021 - 2033 (USD Billion)

Chapter 5. End Use Business Analysis

  • 5.1. Advanced Cancer Diagnostics Market: End Use Movement Analysis, 2024 & 2033
  • 5.2. Hospitals & Cancer Specialty Centers
    • 5.2.1. Hospitals & Cancer Specialty Centers Market, 2021 - 2033 (USD Billion)
  • 5.3. Diagnostic Laboratories
    • 5.3.1. Diagnostic Laboratories market, 2021 - 2033 (USD Billion)
  • 5.4. Research & Academic Institutes
    • 5.4.1. Research & Academic Institutes market, 2021 - 2033 (USD Billion)
  • 5.5. Pharmaceutical & Biotechnology Companies
    • 5.5.1. Pharmaceutical & Biotechnology Companies market, 2021 - 2033 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others Institutes market, 2021 - 2033 (USD Billion)

Chapter 6. Regional Business Analysis

  • 6.1. Regional Market Snapshot
  • 6.2. North America
    • 6.2.1. North America Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.2.2.2. Key Country Dynamics
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. Competitive Scenario
    • 6.2.3. Canada
      • 6.2.3.1. Canada Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.2.3.2. Key Country Dynamics
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Competitive Scenario
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.2.4.2. Key Country Dynamics
      • 6.2.4.3. Regulatory Framework
      • 6.2.4.4. Competitive Scenario
  • 6.3. Europe
    • 6.3.1. Europe Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.3.2. Germany
      • 6.3.2.1. Germany Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.2.2. Key Country Dynamics
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Competitive Scenario
    • 6.3.3. UK
      • 6.3.3.1. UK Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.3.2. Key Country Dynamics
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Competitive Scenario
    • 6.3.4. France
      • 6.3.4.1. France Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.4.2. Key Country Dynamics
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Competitive Scenario
    • 6.3.5. Italy
      • 6.3.5.1. Italy Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.5.2. Key Country Dynamics
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Competitive Scenario
    • 6.3.6. Spain
      • 6.3.6.1. Spain Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.6.2. Key Country Dynamics
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Competitive Scenario
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.7.2. Key Country Dynamics
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Competitive Scenario
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.8.2. Key Country Dynamics
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Competitive Scenario
    • 6.3.9. Norway
      • 6.3.9.1. Norway Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.9.2. Key Country Dynamics
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Competitive Scenario
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.4.2.2. Key Country Dynamics
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Competitive Scenario
    • 6.4.3. China
      • 6.4.3.1. China Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.4.3.2. Key Country Dynamics
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Competitive Scenario
    • 6.4.4. India
      • 6.4.4.1. India Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.4.4.2. Key Country Dynamics
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Competitive Scenario
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.4.5.2. Key Country Dynamics
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Competitive Scenario
    • 6.4.6. Australia
      • 6.4.6.1. Australia Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.4.6.2. Key Country Dynamics
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Competitive Scenario
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.4.7.2. Key Country Dynamics
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Competitive Scenario
  • 6.5. Latin America
    • 6.5.1. Latin America Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.5.2. Key Country Dynamics
    • 6.5.3. Regulatory Framework
    • 6.5.4. Competitive Scenario
    • 6.5.5. Brazil
      • 6.5.5.1. Brazil Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.5.5.2. Key Country Dynamics
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Competitive Scenario
    • 6.5.6. Argentina
      • 6.5.6.1. Argentina Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.5.6.2. Key Country Dynamics
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Competitive Scenario
  • 6.6. MEA
    • 6.6.1. MEA Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.6.2.2. Key Country Dynamics
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Competitive Scenario
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.6.3.2. Key Country Dynamics
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Competitive Scenario
    • 6.6.4. UAE
      • 6.6.4.1. UAE Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.6.4.2. Key Country Dynamics
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Competitive Scenario
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.6.5.2. Key Country Dynamics
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Competitive Scenario

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
    • 7.2.1. Acquisition
    • 7.2.2. Collaborations
    • 7.2.3. New Platform Launches
    • 7.2.4. Others
  • 7.3. Company Profiles/Listing
    • 7.3.1. Fujifilm Holdings Corporation
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Financial Performance
      • 7.3.1.3. Platform Benchmarking
      • 7.3.1.4. Strategic Initiatives
    • 7.3.2. GE Healthcare
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Financial Performance
      • 7.3.2.3. Platform Benchmarking
      • 7.3.2.4. Strategic Initiatives
    • 7.3.3. Siemens Healthineers
      • 7.3.3.1. Company Overview
      • 7.3.3.2. Financial Performance
      • 7.3.3.3. Platform Benchmarking
      • 7.3.3.4. Strategic Initiatives
    • 7.3.4. Philips Healthcare
      • 7.3.4.1. Company Overview
      • 7.3.4.2. Financial Performance
      • 7.3.4.3. Platform Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Thermo Fisher Scientific
      • 7.3.5.1. Company Overview
      • 7.3.5.2. Financial Performance
      • 7.3.5.3. Platform Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. Illumina, Inc.
      • 7.3.6.1. Company Overview
      • 7.3.6.2. Financial Performance
      • 7.3.6.3. Platform Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. Agilent Technologies
      • 7.3.7.1. Company Overview
      • 7.3.7.2. Financial Performance
      • 7.3.7.3. Platform Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Bio-Rad Laboratories
      • 7.3.8.1. Company Overview
      • 7.3.8.2. Financial Performance
      • 7.3.8.3. Platform Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. Canon Medical Systems
      • 7.3.9.1. Company Overview
      • 7.3.9.2. Financial Performance
      • 7.3.9.3. Platform Benchmarking
      • 7.3.9.4. Strategic Initiatives
    • 7.3.10. Bruker Corporation
      • 7.3.10.1. Company Overview
      • 7.3.10.2. Financial Performance
      • 7.3.10.3. Platform Benchmarking
      • 7.3.10.4. Strategic Initiatives
    • 7.3.11. BD
      • 7.3.11.1. Company Overview
      • 7.3.11.2. Financial Performance
      • 7.3.11.3. Platform Benchmarking
      • 7.3.11.4. Strategic Initiatives
    • 7.3.12. Bio-Rad Laboratories
      • 7.3.12.1. Company Overview
      • 7.3.12.2. Financial Performance
      • 7.3.12.3. Platform Benchmarking
      • 7.3.12.4. Strategic Initiatives
    • 7.3.13. Myriad Genetics
      • 7.3.13.1. Company Overview
      • 7.3.13.2. Financial Performance
      • 7.3.13.3. Platform Benchmarking
      • 7.3.13.4. Strategic Initiatives
    • 7.3.14. Roche Diagnostics
      • 7.3.14.1. Company Overview
      • 7.3.14.2. Financial Performance
      • 7.3.14.3. Platform Benchmarking
      • 7.3.14.4. Strategic Initiatives
    • 7.3.15. F. Hoffmann-La Roche Ltd.
      • 7.3.15.1. Company Overview
      • 7.3.15.2. Financial Performance
      • 7.3.15.3. Platform Benchmarking
      • 7.3.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 4 Global Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 5 Global Advanced Cancer Diagnostics Market, by Region, 2021 - 2033 (USD Billion)
  • Table 6 North America Advanced Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Billion)
  • Table 7 North America Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 8 North America Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 9 U.S Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 10 U.S Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 11 Canada Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 12 Canada Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 13 Mexico Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 14 Mexico Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 15 Europe Advanced Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Billion)
  • Table 16 Europe Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 17 Europe Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 18 UK Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 19 UK Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 20 Germany Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 21 Germany Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 22 France Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 23 France Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 24 Italy Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 25 Italy Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 26 Spain Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 27 Spain Advanced Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Billion)
  • Table 28 Norway Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 29 Norway Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 30 Sweden Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 31 Sweden Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 32 Denmark Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 33 Denmark Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 34 Asia Pacific Advanced Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Billion)
  • Table 35 Asia Pacific Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 36 Asia Pacific Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 37 Japan Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 38 Japan Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 39 China Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 40 China Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 41 India Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 42 India Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 43 Australia Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 44 Australia Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 45 South Korea Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 46 South Korea Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 47 Thailand Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 48 Thailand Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 49 Latin America Advanced Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Billion)
  • Table 50 Latin America Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 51 Latin America Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 52 Brazil Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 53 Brazil Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 54 Argentina Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 55 Argentina Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 56 Middle East Africa Advanced Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Billion)
  • Table 57 Middle East Africa Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 58 Middle East Africa Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 59 South Africa Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 60 South Africa Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 61 Saudi Arabia Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 62 Saudi Arabia Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 63 UAE Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 64 UAE Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 65 Kuwait Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 66 Kuwait Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration & Growth Prospect Mapping, 2024
  • Fig. 15 Global Advanced Cancer Diagnostics Market: Test Movement Analysis
  • Fig. 16 Global Tumor Marker Tests Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 17 Global Fine Needle Aspiration Cytology (FNAC) & Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 18 Global Imaging-Based Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 19 Global Bone Marrow Aspiration & Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 20 Global Immunohistochemistry (IHC) & Molecular Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 21 Global Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 22 Global Liquid Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 23 Global Advanced Cancer Diagnostics Market: End Use Movement Analysis
  • Fig. 24 Global Hospitals & Cancer Specialty Centers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 25 Global Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 26 Global Research & Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 27 Global Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 28 Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 Regional Outlook, 2024 & 2033
  • Fig. 31 Global Advanced Cancer Diagnostics Market: Regional Movement Analysis
  • Fig. 32 North America Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 33 U.S. Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 34 Canada Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 35 Mexico Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 36 Europe Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 37 Germany Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 38 UK Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 39 France Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 40 Italy Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 41 Spain Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 42 Denmark Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 43 Sweden Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 44 Norway Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 45 Asia Pacific Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 46 Japan Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 47 China Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 48 India Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 49 Australia Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 50 South Korea Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 51 Thailand Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 52 Latin America Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 53 Brazil Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 54 Argentina Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 55 Middle East And Africa Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 56 South Africa Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 57 Saudi Arabia Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 58 UAE Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 59 Kuwait Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)